Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wai Chun Bio-Technology Ltd. ( (HK:0660) ) has shared an announcement.
Wai Chun Bio-Technology Ltd. reported its unaudited interim results for the six months ending December 31, 2024, showing a decrease in revenue from HK$190,330,000 in 2023 to HK$161,056,000 in 2024. Despite a slight increase in gross profit, the company experienced a significant increase in net loss, with a loss before tax of HK$11,202,000 compared to HK$2,845,000 in the previous year, primarily due to higher administrative expenses and finance costs.
More about Wai Chun Bio-Technology Ltd.
Wai Chun Bio-Technology Ltd. is a company incorporated in the Cayman Islands, focusing on biotechnology products and services. The company is listed on the Stock Exchange of Hong Kong and operates in the biotech industry.
YTD Price Performance: 64.29%
Average Trading Volume: 201,720
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$19.72M
See more insights into 0660 stock on TipRanks’ Stock Analysis page.